絞り込み

16525

広告

ウマが人の行動を認識するのは「声」と「表情」の関連から (NHK)

移動の足などとして数千年前から家畜化が進んだウマは、人の声と表情の2つを関連づけて人の行動を認識していることが北海道大学などの実験でわかりました。身近な動物が人...

  1. 医療保険より100倍マシ! 学資保険の選...
  2. 食べられない高齢者にはこう介入する
  3. 血友病Aに週1回皮下注射の抗体医薬登場
  4. 39歳女性。胃痛、胸焼け

ニュース一覧

Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives.

著者 Donadini MP , Ageno W
Hamostaseologie.2018 May ; 38(2):75-86.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 0users)

Full Text Sources

Pulmonary embolism is associated with variable risk of early mortality, ranging from less than 1% to more than 15%. Risk stratification, based on clinical variables and signs of right ventricular dysfunction, is crucial to decide the best management and treatment strategy. Home therapy may be an option for low-risk patients, whereas patients at intermediate risk need to be hospitalized and some of them, at intermediate high risk, may require more intensive monitoring to early detect signs of haemodynamic decompensation. The initial treatment is based on anticoagulants with rapid onset of action, either parenteral (heparin/fondaparinux) or oral (direct oral anticoagulants, DOACs). Thereafter, DOACs (or, if contraindicated, vitamin K antagonists) needs to be continued for at least 3 months. Beyond this period, an individual re-evaluation of the risk-to-benefit ratio of anticoagulation should be performed, based on several factors, including the type of index event, age, sex, D-dimer and residual venous obstruction. Possibly safer strategies can be offered to higher risk patients requiring extended duration of treatment, including the DOACs apixaban and rivaroxaban at reduced dose.
PMID: 29843172 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード